Screener
Prime Medicine PRME Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income, net | 1,176 | 786 | 2,708 | 1,288 |
| Net loss attributable to common stockholders | $(42,109) | $(52,591) | $(91,231) | $(104,481) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.24) | $(0.41) | $(0.51) | $(0.81) |
| Weighted-average common shares outstanding, basic and diluted | 177,224,892 | 129,185,918 | 177,160,914 | 128,439,349 |
| Comprehensive loss: | ||||
| Net loss | $(42,109) | $(52,591) | $(91,231) | $(104,481) |
| Change in unrealized (loss) income on investments, net of tax | (8) | 5 | (91) | (11) |
| Comprehensive loss | $(42,117) | $(52,586) | $(91,322) | $(104,492) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's business segments — net loss?
- Prime Medicine (PRME) reported business segments — net loss of -$42.11M in Q2 2026.
- How has Prime Medicine's business segments — net loss changed year-over-year?
- Prime Medicine's business segments — net loss increased by 19.9% year-over-year, from -$52.59M to -$42.11M.
- What is the long-term trend for Prime Medicine's business segments — net loss?
- Over 2 years (2023 to 2025), Prime Medicine's business segments — net loss has grown at a 0.8% compound annual growth rate (CAGR), from -$198.13M to -$201.14M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result for a business segment when total operating expenses exceed total revenues. For early-stage biotechnology companies, this metric is a standard measure of the capital required to fund ongoing research and development efforts. It highlights the segment's current reliance on external funding or corporate-level support.
Ask your AI about Prime Medicine's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude